11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Docetaxel Nordic

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Docetaxel

Docetaxel

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.

  2. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.

  3. Socialstyrelsen. Cancer i siffror 2018. Socialstyrelsen [www]. [updated 2018-06-10, cited 2020-10-01].

  4. Docetaxel Accord (docetaxel). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2020-10-01, cited 2020-10-01]

  5. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009;85(2):155-63.

  6. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 2002;20(17):3683-90.

  7. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res. 2012;18(16):4433-40.

  8. Fajac A, Gligorov J, Rezai K, Lévy P, Lévy E, Selle F, Beerblock K, Avenin D, Saintigny P, Hugonin S, Bernaudin JF, Lokiec F. Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010;103(4):560-6.

  9. Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol. 2010;28(30):4562-7.

  10. Nieuweboer AJ, de Morrée ES, de Graan AJ, Sparreboom A, de Wit R, Mathijssen RH. Inter-patient variability in docetaxel pharmacokinetics: A review. Cancer Treat Rev. 2015;41(7):605-13.

  11. European Medicines Agency (EMA). Taxotere (docetaxel) - Scientific Discussion. [updated 2006-06-01, cited 2020-10-01].

  12. Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res. 2006;12(18):5481-90.

  13. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]

  1. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.
  2. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.
  3. Socialstyrelsen. Cancer i siffror 2018. Socialstyrelsen [www]. [updated 2018-06-10, cited 2020-10-01].
  4. Docetaxel Accord (docetaxel). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2020-10-01, cited 2020-10-01]
  5. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009;85(2):155-63.
  6. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 2002;20(17):3683-90.
  7. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res. 2012;18(16):4433-40.
  8. Fajac A, Gligorov J, Rezai K, Lévy P, Lévy E, Selle F, Beerblock K, Avenin D, Saintigny P, Hugonin S, Bernaudin JF, Lokiec F. Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010;103(4):560-6.
  9. Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol. 2010;28(30):4562-7.
  10. Nieuweboer AJ, de Morrée ES, de Graan AJ, Sparreboom A, de Wit R, Mathijssen RH. Inter-patient variability in docetaxel pharmacokinetics: A review. Cancer Treat Rev. 2015;41(7):605-13.
  11. European Medicines Agency (EMA). Taxotere (docetaxel) - Scientific Discussion. [updated 2006-06-01, cited 2020-10-01].
  12. Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res. 2006;12(18):5481-90.
  13. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]